ClinicalTrials.gg
Active, not recruitingNCT05245968Updated Jan 20, 2026

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

A Phase 1 interventional study of Pimitespib and Imatinib in Gastrointestinal Stromal Tumors, sponsored by Taiho Pharmaceutical Co., Ltd.. Active, not recruiting at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies testing sunitinib in Gastrointestinal Stromal Tumors — 1 open to participants now, 2 under way, none of them phase 3. Sunitinib · Gastrointestinal Stromal Tumors.

Planned enrollment
3rd of 13
78 · median 54
Started
2021
the only one that year
Phase 1
2 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Taiho Pharmaceutical Co., Ltd.

Among the 13 studies testing sunitinib in Gastrointestinal Stromal Tumors, this one is the 3rd largest by planned enrollment, is the only one that started in 2021, is one of 2 in phase 1, and was the 12th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

1 of the 13 studies testing sunitinib in Gastrointestinal Stromal Tumors is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sunitinib

Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing sunitinib in Gastrointestinal Stromal Tumors, or all of them as a file.
02

Study summary

This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged to be refractory to imatinib, estimate the recommended dose, evaluate safety and pharmacokinetics, and observe the antitumor effect. Expansion part consists of 3 arms. In Arm A, the efficacy and safety will be evaluated, which of the combination of pimitespib and imatinib in patients with GIST who have failed imatinib at doses below the MTD determined in Dose Escalation Part. In Arm B, the efficacy and safety of pimitespib monotherapy will be evaluated and the therapeutic effect of imatinib administration after pimitespib will be evaluated in an exploratory manner. In Arm C, the efficacy and safety of sunitinib monotherapy will be evaluated as reference data.

03

Conditions studied

  • Gastrointestinal Stromal Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided written
  • confirmed GIST
  • Has radiographic progression based on 1.1 during or within 6 months of the last imatinib administration at enrollment. If surgery/radiotherapy has been performed, radiographic progression based on RECIST 1.1 with imatinib must have been observed after the last surgery /radiotherapy
  • Has at least one based on the RECIST version 1.1, except lymph nodes (not dependent on size), which should be chosen as nontarget lesions;
  • (ECOG) performance status of 0 to 1

Exclusion criteria

Exclusion Criteria:

  • Corrected visual acuity \< 0.5 (using the International Visual Acuity Measurement Standard) for both eyes
  • Received treatment with any other besides imatinib for advanced GIST
  • History of total gastrectomy and/or whole resection of the small intestine
  • A serious illness or medical condition
  • Previous or concurrent cancer that is distinct in primary disease or histology from cancer that is being evaluated in this study. However, any previous cancer curatively treated > 5 years before the enrollment can be eligible
  • Pregnancy or lactation (including lactation interruption)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Part

    Pimitespib in combination with imatinib

    Drug: Pimitespib · Drug: Imatinib

  • Experimental
    Expansion Part-A

    Pimitespib in combination with imatinib

    Drug: Pimitespib · Drug: Imatinib

  • Experimental
    Expansion Part-B

    Pimitespib followed by imatinib

    Drug: Pimitespib · Drug: Imatinib

  • Experimental
    Expansion Part-C

    Sunitinib

    Drug: Sunitinib

Interventions

  • Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.

    Also known as: TAS-116

  • Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.

  • Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) of pimitespib in combination with imatinib

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Maximum tolerable dose (MTD) of pimitespib in combination with imatinib

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  3. Progression-free survival (PFS)

    Time frame: approximately 2 years

Secondary outcomes

  1. Overall survival (OS)

    Time frame: approximately 2 years

  2. Overall response rate (ORR)

    Time frame: approximately 2 years

  3. Disease control rate (DCR)

    Time frame: approximately 2 years

  4. Duration of response (DoR)

    Time frame: approximately 2 years

  5. Adverse event (AE)

    Time frame: approximately 2 years

  6. Adverse drug reaction (ADR)

    Time frame: approximately 2 years

  7. Maximum plasma concentration (Cmax)

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  8. Time to reach maximum plasma concentration (Tmax)

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  9. Under the plasma concentration-time curve up to the last observable concentration (AUC0-last)

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  10. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  11. λz

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  12. Half-life (T1/2)

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  13. Oral clearance (CL/F)

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  14. Apparent volume of distribution (Vz/F)

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  15. Mean residence time (MRT)

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  16. Accumulation ratio

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

  17. Metabolite ratio

    Time frame: Multiple time points on Day 1 and Day5 or Day12 of Cycle 1 (each cycle is 28 days)

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: Yes — Taiho provides a platform for accepting researchers' requests for sharing anonymized, patient-level, analyzable datasets from articles published in peer-reviewed journals about the primary results from Taiho-sponsored interventional clinical trials in patients in which the medicine and the indication has received marketing approval from regulatory authorities in the United States, the European Union, and/or Japan on or after January 15, 2018.

Supporting information: Study protocol, Statistical analysis plan

Time frame: https://www.taiho.co.jp/en/science/policy/clinical_trial_information_disclosure_policy/index.html

Access criteria: Access to the clinical trial data is contingent upon approval of a proposed study protocol by an independent review panel and the execution of a data-sharing agreement with the researcher.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2022
First posted
Feb 18, 2022
StartActual
Dec 1, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05245968
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Dec 1, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

Taiho Pharmaceutical Co., Ltd.
study director · Taiho Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pimitespib · Sunitinib

Start the discussion